Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) to Post Q1 2024 Earnings of ($0.31) Per Share, Zacks Small Cap Forecasts

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) – Research analysts at Zacks Small Cap issued their Q1 2024 earnings estimates for shares of Tonix Pharmaceuticals in a report released on Monday, April 29th. Zacks Small Cap analyst D. Bautz anticipates that the company will post earnings of ($0.31) per share for the quarter. The consensus estimate for Tonix Pharmaceuticals’ current full-year earnings is ($3.71) per share. Zacks Small Cap also issued estimates for Tonix Pharmaceuticals’ FY2026 earnings at ($0.62) EPS.

A number of other brokerages have also recently issued reports on TNXP. StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research note on Saturday, April 27th. They issued a “sell” rating on the stock. Dawson James assumed coverage on shares of Tonix Pharmaceuticals in a research note on Wednesday, February 28th. They set a “buy” rating and a $3.00 target price on the stock.

Tonix Pharmaceuticals Price Performance

NASDAQ:TNXP opened at $0.18 on Tuesday. The firm’s 50-day moving average price is $0.26 and its 200-day moving average price is $0.37. The company has a market capitalization of $14.95 million, a PE ratio of -0.02 and a beta of 2.21. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.53 and a quick ratio of 1.81. Tonix Pharmaceuticals has a 1-year low of $0.12 and a 1-year high of $3.31.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Monday, April 1st. The company reported ($0.86) earnings per share (EPS) for the quarter. The business had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.95 million.

Institutional Investors Weigh In On Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. Sabby Management LLC acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 1,247,465 shares of the company’s stock, valued at approximately $680,000. Tonix Pharmaceuticals makes up about 0.5% of Sabby Management LLC’s holdings, making the stock its 6th biggest position. Sabby Management LLC owned about 7.02% of Tonix Pharmaceuticals as of its most recent filing with the SEC. Institutional investors and hedge funds own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.